---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-029119"
form_type: "8-K"
ticker: "ACHV"
cik: "0000949858"
company_name: "ACHIEVE LIFE SCIENCES, INC."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T01:16:56.568823+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Achieve Life Sciences Q2 net loss $10.5M; Phase 3 success and $2.5M NIH grant

## Summary
- Q2 2022 net loss of $10.5M; operating expenses $10.1M; cash & restricted cash $29.4M as of June 30.
- Phase 3 ORCA-2 trial in 810 smokers: 6–8x increased odds of smoking abstinence vs placebo (statistically significant).
- Awarded $2.5M NIH grant for Phase 2 ORCA-V1 trial evaluating cytisinicline in e-cigarette users; trial initiated.
- ORCA-3, the final NDA-enabling smoking cessation trial, continues enrolment.

## SEC filing metadata
- accession: 0001564590-22-029119
- form_type: 8-K
- ticker: ACHV
- cik: 0000949858
- company_name: ACHIEVE LIFE SCIENCES, INC.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/949858/000156459022029119/0001564590-22-029119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/949858/000156459022029119/achv-8k_20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-029119
- JSON: https://secwatch.observer/filing/0001564590-22-029119.json
- Plain text: https://secwatch.observer/filing/0001564590-22-029119.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.